logo
Why Biden may not have known about his 'aggressive' prostate cancer until recently

Why Biden may not have known about his 'aggressive' prostate cancer until recently

Yahoo19-05-2025

Former President Joe Biden's office announced on Sunday that he was diagnosed with an "aggressive" form of prostate cancer.
Biden's office also said the cancer had metastasized, spreading to his bones.
Although some people were left wondering why the cancer was caught only after reaching a Gleason score of 9, oncology experts told ABC News that it's not uncommon for older prostate cancer patients to receive a diagnosis after the disease has advanced or spread.
MORE: What to know about prostate cancer after former President Joe Biden's diagnosis
"Prostate cancer is something that we always hope screening will identify early, when the cancer is all still inside the prostate," Dr. Alicia Morgans, a genitourinary medical oncologist at Dana-Farber Cancer Institute in Boston and a member of the board of directors of the no-profit Zero Prostate Cancer, told ABC News.
"Even if we screen everybody perfectly, there will never be 100% detection of prostate cancer because, in truth, cancer does not follow a rule book," Morgans continued. "And just because we are trying to catch it early doesn't mean it necessarily is present when we screen."
One screening test for prostate cancer involves a blood test that measures the level of prostate-specific antigens, which are proteins made by cells in the prostate gland.
Although there is no cutoff level that clearly indicates the presence of cancer, many doctors use a cutoff of 4 nanograms per milliliter to recommend further tests with a urologist, according to the American Cancer Society.
For an advanced form of cancer like Biden's, a recent PSA test would have likely shown elevated levels.
However, the U.S. Preventive Services Task Force recommends against PSA-based screening for men age 70 and older due to harms such as false positives leading to more tests or a diagnosis of problems that would not have caused symptoms or death.
MORE: Former President Joe Biden's cancer diagnosis: What does a Gleason score of 9 mean?
Morgans said it's unclear what the former president and his doctor discussed regarding screening, but it's plausible that he did not undergo PSA screening.
"It is absolutely possible that President Biden, like so many men over that age, have decided to stop doing PSA screening because they've decided that it is not consistent with their overall health goals and wishes, and that is completely reasonable," Morgans said.
Morgans said some men in their 70s and 80s do still undergo PSA screening for prostate cancer based on conversations with their primary care physicians and what's right for them.
Even so, it's possible that the results were normal -- either due to a false negative or because their cancer was not present at the time, she said.
"Prostate cancer can develop between screening tests," Morgans said. "It doesn't necessarily grow super slowly. It can develop between screenings, and it can be aggressive when it does develop; that doesn't mean it's not treatable."
Dr. Alan Bryce, chief clinical officer for City of Hope Cancer Center Phoenix, said there may be some patients who receive PSA screening results showing borderline-high results who decide not to pursue further testing.
"There are absolutely scenarios where that conversation happens with a patient or their family member," Bryce told ABC News. "All of them might say, 'You know what? Given where we're at in life, we're not that worried about this. Let's go ahead and wait another year.'"
MORE: 'Strongest in the broken places': Joe and Jill Biden say thanks amid cancer diagnosis
Bryce, a medical oncologist specializing in prostate and testicular cancers, added that shared decision-making is important when it comes to deciding if a patient wants to pursue prostate cancer screening -- and if they want to test further following test results that are abnormal.
"As physicians, we present patients with options and recommendations but, at the end of the day, it's still the patient's decision," he said. "So, it's entirely possible that a conversation happens and the patient decides they don't want to proceed with further workup. Maybe they don't want to do a scan, maybe they don't want to do a biopsy."
Advanced prostate cancer can present symptoms such as a weak urination stream; needing to urinate more often; erectile dysfunction; fatigue; weight loss; loss of bladder or bowel control; and pain in the ribs, hips and spine when the cancer had spread to the bones, according to the ACS.
Morgans said just because a patient has advanced prostate cancer, it doesn't necessarily mean that they will exhibit symptoms.
"I would say that it's more common than not that people sit in my office and tell me, 'You know, I don't have any symptoms. I don't understand how I have this cancer. I certainly don't understand how it could have spread outside of my prostate,'" Morgans said. "It is very common for people to be completely asymptomatic."
Bryce added that some symptoms, such as difficulty urinating or a weak urination stream, may be due to an enlarged prostate, which is common in older men.
"It is entirely normal that in older men, there is a degree of urinary obstruction that just happens with age," he said. "It's entirely possible that a man just has normal symptoms associated with aging and nothing about it stands out as being related to a cancerous process."
Why Biden may not have known about his 'aggressive' prostate cancer until recently originally appeared on abcnews.go.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

8 ice cream flavors recalled in Ohio
8 ice cream flavors recalled in Ohio

Yahoo

time27 minutes ago

  • Yahoo

8 ice cream flavors recalled in Ohio

WAUSEON, Ohio — An Ohio-based creamery has announced a voluntary recall due to undeclared allergens in eight of their ice cream flavors. According to the Ohio Department of Agriculture, Turkeyfoot Creek Creamery of Wauseon, Ohio, is recalling the following flavors of ice cream; Avalanche, Chocolate Peanut Butter, Chocolate Strawberry, Chocolate Brownie Bites, Cookies and Cream, Cookie Dough, Cacao and Mocha. Massive egg recall hits Ohio Walmart stores The affected products are all packaged in pint containers and were distributed to six stores, located in Canton, Cleveland, West Unity, and Arlington, Ohio. As well, as two stores located out of state, with one in Fort Wayne, Indiana, and the other in Hudson, Michigan, read a press release from the Ohio Department of Agriculture. Young mother killed in shooting at Cleveland Metroparks Mill Creek Falls 'There have been no reports of illness involving products addressed in this recall, however, individuals exhibiting signs or symptoms of an allergic reaction after consuming Turkeyfoot Creek Creamery Ice Cream involved in this recall should contact a physician immediately,' stated the release. All affected products have been removed from store shelves. Consumers can return recalled products to the place of purchase for a refund. Consumers with questions can call 419-583-7124. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Topeka's KMC Dermatology Is First in Kansas to Offer Nonsurgical GentleCure™ Treatment Option for Common Skin Cancer
Topeka's KMC Dermatology Is First in Kansas to Offer Nonsurgical GentleCure™ Treatment Option for Common Skin Cancer

Yahoo

time44 minutes ago

  • Yahoo

Topeka's KMC Dermatology Is First in Kansas to Offer Nonsurgical GentleCure™ Treatment Option for Common Skin Cancer

BURR RIDGE, Ill., June 11, 2025 /PRNewswire/ -- SkinCure Oncology, the industry leader in providing a comprehensive cancer center model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT or IGSRT) for the treatment of nonmelanoma skin cancer (NMSC), presented to dermatology patients and professionals as the GentleCure Experience™, today announced its first availability in Kansas at an event at Topeka's KMC Dermatology. Image-Guided SRT is the only treatment for nonmelanoma skin cancer (basal and squamous cell carcinoma) that uses ultrasound imaging to help clinicians direct low-level x-rays to targeted areas of the skin, killing cancer cells. For patients treated with Image-Guided SRT, the cure rate (freedom from recurrence at six years) has been shown to be greater than 99 percent, with researchers reporting that for appropriately selected early-stage nonmelanoma skin cancers, Image-Guided SRT is a clinically equivalent alternative to Mohs surgery and statistically significant in superiority to non-Image-Guided SRT. Dr. Joseph Gadzia of KMC Derm noted, "More than 26,000 individuals in Kansas are expected to be diagnosed with nonmelanoma skin cancer this year. We know that sun exposure is the main cause of this type of cancer but there are other factors as well. For those who have been diagnosed with nonmelanoma skin cancer, we now offer a nonsurgical treatment option which we call the GentleCure Experience, and we are proud to be the first practice in the state to offer it." Dr. Gadzia also added, "While most common skin cancers have been treated with Mohs surgery, this newer treatment option achieves close to the same success rate with no surgery, no surgical scarring, and no bleeding. As of this past April, more than 100,000 patients have been successfully treated with Image-Guided SRT in the United States." Other speakers included Dr. Shekhar Challa; U.S. Senator Roger Marshall via video; Topeka Mayor Michael Padilla; Aaron Mays, Chairman of the Shawnee County Board of Commissioners; and John Mugler, District Director, Office of Senator Marshall. In addition, Kansas Governor Laura Kelly issued a gubernatorial proclamation declaring June 8 – 14 "Kansas Nonmelanoma Skin Cancer Awareness Week," noting that KMC Dermatology is the first practice in the state of Kansas to offer Image-Guided SRT. Kerwin Brandt, chief executive officer of Chicago-based SkinCure Oncology, said, "We are delighted to partner with KMC Dermatology to offer this highly effective, noninvasive treatment option for their patients. It is critical that patients everywhere have the choice of treating their nonmelanoma skin cancer without surgery." About SkinCure OncologySkinCure Oncology is the industry leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT or IGSRT), the most advanced nonsurgical treatment for common skin cancer. The company partners with quality-focused dermatologists, Mohs surgeons and other physicians to bring cancer center-level radiation therapy treatment to private practices. Presented to patients as the GentleCure Experience™, Image-Guided SRT is available from some 500 physicians nationwide, with more than 100,000 patients having been treated. Learn more about the company at and visit for helpful consumer and patient information. Media Contact:Matt RussellRussell Public Communications520-232-9840mrussell@ View original content to download multimedia: SOURCE SkinCure Oncology Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Effort to ease cannabis rules faces new opposition from experts
Effort to ease cannabis rules faces new opposition from experts

Boston Globe

time2 hours ago

  • Boston Globe

Effort to ease cannabis rules faces new opposition from experts

The US Department of Health and Human Services during President Joe Biden's term made the case that cannabis warrants rescheduling because it's already widely used as medicine in state programs to offer relief for conditions such as chronic pain, and carries a lower potential for abuse and harm than substances like opioids. Advertisement However, the study's authors criticized the comparison. 'In essence, HHS' reasoning is tantamount to saying that getting hit by a truck is relatively safe because it's less damaging than getting hit by a train,' the authors said. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up The authors include Bertha Madras, a Harvard Medical School professor and addiction researcher who served on President Donald Trump's 2017 opioid commission. The second author, Paul Larkin, was previously a Justice Department lawyer who's now at the Heritage Foundation, which helped develop the Project 2025 agenda, a conservative policy plan that shares common themes with Trump's policy priorities. They also argue that federal health officials failed to fully consider risks such as youth consumption, rising rates of cannabis-use disorder, cannabis-impaired driving, and growing evidence linking high-potency marijuana to psychosis. Advertisement Rescheduling would move cannabis into a lower-risk category, recognizing its potential medical use. It wouldn't legalize the drug federally but would loosen restrictions, ease tax burdens and make it easier for cannabis companies to access financial services and claim tax deductions. The shift could also spark investment and legalization in more states, analysts say. The effort to reschedule cannabis began in 2022, when Biden instructed federal health and law enforcement agencies to reassess marijuana's status as a Schedule I drug, the government's strictest classification that includes LSD and heroin. The Justice Department later recommended moving cannabis to Schedule III, prompting a formal review by the Drug Enforcement Administration. The rescheduling process has stalled under the current Trump administration, leaving the cannabis industry and investors in limbo. The DEA postponed hearings earlier this year following legal appeals, and federal officials have not announced a new timeline. HHS Secretary Robert F. Kennedy Jr., who previously supported federal decriminalization, recently warned about the public health risks of high-potency marijuana. In February, Kennedy said there is a need for more research on cannabis effects and called for policies to address its harms. The House Appropriations Committee previously called for an investigation into the cannabis rescheduling process. In a report published last July, lawmakers directed the HHS Inspector General to review whether the Biden-era review followed proper standards and encouraged the FDA to study the mental health risks of high-potency marijuana use among adolescents.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store